Research tools
Analyst Ratings Screener
Find recent upgrades, downgrades, initiations, and reiterations by firm, rating, consensus, target upside, sector, and company size.
Save your best screens
Sign in to keep filters and sorting ready for your next visit.
3,971 matching rating changes
Export CSV| Date, sort lowest first | Symbol | Company | Firm | Action | Prior rating | New rating | Consensus | Analysts, sort highest first | Avg. target | Target upside, sort highest first | Market cap, sort highest first |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | AFRM | Affirm Holdings, Inc. | Loop Capital | Initiated | — | Buy | — | — | $94.13 | +33.40% | 15.65B |
| Sep 9, 2026 | AGX | Argan, Inc. | Piper Sandler | Initiated | — | Underweight | — | — | $336.33 | -12.03% | 6.26B |
| Sep 9, 2026 | AKTS | Aktis Oncology, Inc. | Oppenheimer | Initiated | — | Outperform | — | — | $4.92 | -78.24% | 1.06B |
| Sep 9, 2026 | AMRX | Amneal Pharmaceuticals, Inc. | Leerink Partners | Initiated | — | Outperform | — | — | $15.00 | -17.94% | 4.34B |
| Sep 9, 2026 | AMRZ | Amrize Ltd | Wells Fargo | Downgrade | Overweight | Equal-Weight | Buy | 16 | $57.72 | +50.69% | 35.94B |
| Sep 9, 2026 | APAM | Artisan Partners Asset Management Inc. | Evercore ISI Group | Main | In-Line | In-Line | — | — | $45.00 | +22.72% | 2.84B |
| Sep 9, 2026 | APD | Air Products and Chemicals, Inc. | Argus Research | Main | Buy | Buy | Buy | 13 | $286.67 | +0.41% | 61.38B |
| Sep 9, 2026 | APH | Amphenol Corporation | TD Cowen | Main | Hold | Hold | Buy | 11 | $141.40 | +81.35% | 179.54B |
| Sep 9, 2026 | APTV | Aptiv PLC | StoneX | Initiated | — | Buy | Buy | 29 | $94.38 | +115.26% | 15.89B |
| Sep 9, 2026 | ARRY | Array Technologies, Inc. | Piper Sandler | Initiated | — | Neutral | — | — | $10.67 | +149.01% | 1.16B |
| Sep 9, 2026 | AS | Amer Sports, Inc. | BMO Capital | Initiated | — | Outperform | Buy | 29 | $44.23 | +67.89% | 21.06B |
| Sep 9, 2026 | ASO | Academy Sports and Outdoors, Inc. | BMO Capital | Initiated | — | Market Perform | — | — | $58.75 | +16.82% | 4.01B |
| Sep 9, 2026 | AVTR | Avantor, Inc. | UBS | Main | Neutral | Neutral | — | — | $12.50 | -21.33% | 7.82B |
| Sep 9, 2026 | BBOT | BridgeBio Oncology Therapeutics Inc. | Canaccord Genuity | Main | Buy | Buy | — | — | $23.20 | +374.44% | 1.03B |
| Sep 9, 2026 | BBOT | BridgeBio Oncology Therapeutics Inc. | Wedbush | Reiterated | Outperform | Outperform | — | — | $23.20 | +374.44% | 1.03B |
| Sep 9, 2026 | BBOT | BridgeBio Oncology Therapeutics Inc. | Stifel | Main | Buy | Buy | — | — | $23.20 | +374.44% | 1.03B |
| Sep 9, 2026 | BBOT | BridgeBio Oncology Therapeutics Inc. | Raymond James | Main | Outperform | Outperform | — | — | $23.20 | +374.44% | 1.03B |
| Sep 9, 2026 | BBWI | Bath & Body Works, Inc. | BMO Capital | Initiated | — | Market Perform | Hold | 21 | $20.61 | +20.21% | 4.21B |
| Sep 9, 2026 | BEAM | Beam Therapeutics Inc. | Wedbush | Reiterated | Outperform | Outperform | — | — | $38.00 | +53.10% | 2.79B |
| Sep 9, 2026 | BIOA | BioAge Labs, Inc. | Roth Capital | Reiterated | Buy | Buy | — | — | $12.00 | +47.10% | 458.05M |
| Sep 9, 2026 | BIRK | Birkenstock Holding plc | BMO Capital | Initiated | Outperform | Market Perform | — | — | $68.50 | +118.19% | 8.44B |
| Sep 9, 2026 | BLCO | Bausch + Lomb Corporation | Leerink Partners | Initiated | — | Outperform | Hold | 20 | $18.00 | +7.27% | 6.12B |
| Sep 9, 2026 | BLK | BlackRock, Inc. | Evercore ISI Group | Main | Outperform | Outperform | Buy | 11 | $1,304.50 | +23.22% | 170.74B |
| Sep 9, 2026 | BLTE | Belite Bio, Inc | Mizuho | Main | Outperform | Outperform | — | — | $191.50 | +13.65% | 5.24B |
| Sep 9, 2026 | BNED | Barnes & Noble Education, Inc. | Needham | Reiterated | Buy | Buy | — | — | $2.38 | -77.87% | 311.42M |
| Sep 9, 2026 | BRKR | Bruker Corporation | UBS | Main | Neutral | Neutral | Buy | 20 | $49.71 | -21.43% | 7.04B |
| Sep 9, 2026 | BRKRP | Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A | UBS | Main | Neutral | Neutral | Buy | 12 | — | — | 54.39B |
| Sep 9, 2026 | BRZE | Braze, Inc. | Citizens | Reiterated | Market Outperform | Market Outperform | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | Needham | Reiterated | Buy | Buy | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | Stephens & Co. | Main | Overweight | Overweight | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | BTIG | Reiterated | Buy | Buy | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | Piper Sandler | Reiterated | Overweight | Overweight | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | Canaccord Genuity | Main | Buy | Buy | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | Raymond James | Main | Outperform | Outperform | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | UBS | Main | Buy | Buy | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | DA Davidson | Main | Buy | Buy | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BRZE | Braze, Inc. | JP Morgan | Main | Overweight | Overweight | — | — | $44.63 | +79.05% | 3.71B |
| Sep 9, 2026 | BSX | Boston Scientific Corporation | BTIG | Main | Buy | Buy | Buy | 24 | $127.00 | +193.74% | 135.98B |
| Sep 9, 2026 | BXP | BXP, Inc. | Truist Securities | Main | Hold | Hold | Hold | 27 | $80.17 | +24.89% | 11.35B |
| Sep 9, 2026 | CAI | Caris Life Sciences, Inc. | UBS | Initiated | — | Neutral | Buy | 12 | $35.00 | +12.89% | 7.49B |
| Sep 9, 2026 | CAN | Canaan Inc. | Rosenblatt | Main | Buy | Buy | — | — | $2.92 | +813.93% | 416.4M |
| Sep 9, 2026 | CAN | Canaan Inc. | BTIG | Main | Buy | Buy | — | — | $2.92 | +813.93% | 416.4M |
| Sep 9, 2026 | CASY | Casey's General Stores, Inc. | Wells Fargo | Main | Overweight | Overweight | Buy | 20 | $585.67 | -4.20% | 20.15B |
| Sep 9, 2026 | CASY | Casey's General Stores, Inc. | RBC Capital | Main | Sector Perform | Sector Perform | Buy | 20 | $585.67 | -4.20% | 20.15B |
| Sep 9, 2026 | CASY | Casey's General Stores, Inc. | Stephens & Co. | Reiterated | Overweight | Overweight | Buy | 20 | $585.67 | -4.20% | 20.15B |
| Sep 9, 2026 | CCG | Cheche Group Inc. | Maxim Group | Downgrade | Buy | Hold | Buy | 5 | — | — | 79.49M |
| Sep 9, 2026 | CHYM | Chime Financial, Inc. Class A Common Stock | Morgan Stanley | Main | Overweight | Overweight | — | — | $30.40 | -2.64% | 10.3B |
| Sep 9, 2026 | CHYM | Chime Financial, Inc. Class A Common Stock | Barclays | Main | Overweight | Overweight | — | — | $30.40 | -2.64% | 10.3B |
| Sep 9, 2026 | CHYM | Chime Financial, Inc. Class A Common Stock | Keybanc | Main | Overweight | Overweight | — | — | $30.40 | -2.64% | 10.3B |
| Sep 9, 2026 | CHYM | Chime Financial, Inc. Class A Common Stock | Canaccord Genuity | Main | Buy | Buy | — | — | $30.40 | -2.64% | 10.3B |
